🔖 What This Document Is

This is an 8-K filing, which is a report a company files with the SEC to announce major, shareholder-affecting news. In this case, Immunic, Inc. (IMUX) is announcing a key addition to its leadership team. Think of it as a formal press release with regulatory weight.

🧬 What The Company Does

👉 In simple terms, Immunic is a late-stage biotech company creating new, oral pills for serious brain and nerve diseases. Their main focus right now is a drug called vidofludimus calcium (IMU-838) for multiple sclerosis (MS). They aim to offer a safer, more convenient treatment option compared to many current injectable therapies.

🧠 The New Board Member

The big news is the appointment of Jon Congleton to Immunic's Board of Directors, effective March 27, 2026.

Why He's a Big Deal:

• He has nearly 40 years of experience in the drug industry.
• He was part of the original team that launched Copaxone® in the U.S., which became the #1 prescribed MS treatment.
• He has been a CEO at several biotech companies and currently leads Mineralys Therapeutics.

👉 His appointment is a strategic hire to guide Immunic from a drug developer into a company that can eventually launch and sell its own medicines.

🚀 Why This Hire Matters

Immunic's lead drug, vidofludimus calcium, is currently in Phase 3 clinical trials for MS, with important results expected by the end of 2026.

Quote from Simona Skerjanec (Interim Board Chair): Jon’s deep expertise will be invaluable as we advance our drug toward potential approval and launch.

Quote from Jon Congleton: He called vidofludimus calcium "potentially transformative" for MS patients, citing its unique combo of neuroprotective, anti-inflammatory, and anti-viral effects.

👉 This hire signals Immunic is serious about preparing for commercialization. They’ve brought in someone who has successfully launched a blockbuster MS drug before.

⏰ What’s Next for Immunic

The company is focused on one primary goal: getting the Phase 3 trial results for its MS drug by the end of 2026. This data will determine if the drug is effective and safe enough for regulatory approval. Jon Congleton’s experience is meant to help navigate this critical phase and the commercial planning that follows.

💡 The Bigger Picture (Strengths & Risks)

• 👍 Strength: Immunic is strengthening its board with proven, relevant expertise exactly when it needs it most—right before pivotal data readouts and a potential transition to a commercial company.
• ⚠️ Risk: The company's success is highly dependent on the upcoming clinical trial results. A setback in the data could significantly impact its future. As a late-stage biotech, it is also likely pre-revenue and burning cash to fund its operations.

🧠 The Analogy

Immunic is like a promising sports team that has made it to the championship finals. They just hired a veteran coach who has won a championship before (Jon Congleton with Copaxone). The coach isn’t playing the game, but his experience in big-game strategy and managing the pressure is exactly what the team needs to have the best chance of winning the final match (the Phase 3 trial results).

📇 Key Contacts & People

• Jon Congleton: New Board Member
• Simona Skerjanec, M.Pharm, MBA: Interim Chairperson of the Board
• Jessica Breu: Vice President Investor Relations and Communications
  • Email: [email protected]
  • Phone: +49 89 2080 477 09
• Paula Schwartz (Rx Communications Group): US IR Contact
  • Email: [email protected]
  • Phone: +1 917 633 7790
• Caitlin Kasunich (KCSA Strategic Communications): US Media Contact
  • Email: [email protected]
  • Phone: +1 212 896 1241

🧩 Final Takeaway

Immunic is strategically bolstering its board with a veteran who knows exactly how to launch a major MS drug. This move underscores the company's focus on its upcoming pivotal trial results and its preparation for a future as a commercial-stage biopharmaceutical company. The appointment de-risks the "go-to-market" part of their strategy, but the core clinical risk of the trial remains.